NATIONAL MARROW DONOR PROGRAM

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1981

Legal Domicile

Principal Officer

AMY RONNEBERG

Phone

7634065800

Tax Period

2023-10-01 to 2024-09-30

NATIONAL MARROW DONOR PROGRAM, founded in 1981, is a major nonprofit in the Health Care sector that reported $666.7M in total revenue in fiscal year 2023. Revenue grew 15% year-over-year, indicating healthy expansion. Expenses of $623.0M left a modest 7% surplus.

Mission

AT NMDP, WE BELIEVE EACH OF US HOLDS THE KEY TO CURING BLOOD CANCERS AND DISORDERS. AS A GLOBAL NONPROFIT LEADER IN CELL THERAPY, NMDP CREATES ESSENTIAL CONNECTIONS BETWEEN RESEARCHERS AND SUPPORTERS TO INSPIRE ACTION AND ACCELERATE INNOVATION TO FIND LIFE-SAVING CURES. WITH THE HELP OF BLOOD STEM DONORS FROM THE WORLD'S MOST DIVERSE REGISTRY AND OUR EXTENSIVE NETWORK OF TRANSPLANT PARTNERS, PHYSICIANS AND CAREGIVERS, WE'RE EXPANDING ACCESS TO TREATMENT SO THAT EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. NMDP. FIND CURES. SAVE LIVES. OUR MISSION: WE SAVE LIVES THROUGH CELL THERAPY. OUR VISION: CREATE A WORLD WHERE EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. THE NMDP FOUNDATION RAISES FUNDS FOR THREE PROGRAMS CRITICAL TO OUR LIFE-SAVING MISSION: TRANSPLANT RESEARCH, PATIENT FINANCIAL ASSISTANCE AND BLOOD STEM CELL DONOR RECRUITMENT. SOME OF THE LIFE-CHANGING WORK THAT WE'RE DOING IS SOLELY FUNDED BY OUR COMMUNITY OF SUPPORTERS. WE CONDUCT RESEARCH THROUGH OUR RESEARCH PROGRAM, CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) IN COLLABORATION WITH THE MEDICAL COLLEGE OF WISCONSIN. OUR RESEARCH LEADS TO MORE LIVES SAVED AND AN ENRICHED QUALITY OF LIFE FOR THOUSANDS OF PATIENTS. THROUGH THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM AND OTHER RESEARCH GRANTS, OUTSTANDING EARLY-CAREER RESEARCHERS ARE DOING INNOVATIVE WORK TO FIND SOLUTIONS TO THE COMPLICATIONS THAT CAN ARISE AFTER TRANSPLANT. THEY'RE DEVELOPING TREATMENT APPROACHES THAT WILL HELP THE NEXT GENERATION OF TRANSPLANT PATIENTS LIVE LONGER AND HEALTHIER LIVES. PATIENT FINANCIAL ASSISTANCE HELPS COVER TRANSPLANT-RELATED COSTS NOT COVERED BY INSURANCE. THESE COSTS, INCLUDING TRANSPORTATION, LODGING, LOST WAGES AND PRESCRIPTIONS, WOULD OTHERWISE CAUSE SIGNIFICANT HARDSHIP FOR PATIENTS OR EVEN PREVENT PATIENTS FROM MOVING FORWARD WITH TRANSPLANT. NMDP CONNECTS PATIENTS WITH A MATCHING, UNRELATED DONOR - A SELFLESS STRANGER WHO CAN STEP UP AND DONATE HEALTHY BLOOD STEM CELLS TO GIVE THEM THE CHANCE AT A LIFE-SAVING TRANSPLANT.

Program Service Accomplishments

Program 1

Expenses: $376,559,625 Revenue: $560,425,776

TRANSPLANT:AT NMDP, WE BELIEVE EACH OF US HOLDS THE KEY TO CURING BLOOD CANCERS AND DISORDERS. AS A GLOBAL NONPROFIT LEADER IN CELL THERAPY, NMDP CREATES ESSENTIAL CONNECTIONS BETWEEN RESEARCHERS AND SUPPORTERS TO INSPIRE ACTION AND ACCELERATE INNOVATION TO FIND LIFE-SAVING CURES. WITH THE HELP OF BLOOD STEM DONORS FROM THE WORLD'S MOST DIVERSE REGISTRY AND OUR EXTENSIVE NETWORK OF TRANSPLANT PARTNERS, PHYSICIANS AND CAREGIVERS, WE'RE EXPANDING ACCESS TO TREATMENT SO THAT EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. NMDP. FIND CURES. SAVE LIVES. CURRENTLY THERE ARE MORE THAN 9 MILLION TOTAL POTENTIAL U.S. DONORS ON THE NMDP REGISTRY. NMDP FACILITATES ALL UNRELATED TRANSPLANTS IN THE U.S., ASSISTING DOCTORS IN SEARCHING MORE THAN 42 MILLION POTENTIAL DONORS WORLDWIDE. NMDP HAS IMPACTED MORE THAN 135,000 LIVES SINCE 1987.

Program 2

Expenses: $67,015,867 Revenue: $18,898,876

RESEARCH:RESEARCH INNOVATIONS ARE CRITICAL TO EXPANDING TREATMENT TO MORE PATIENTS AND IMPROVING OUTCOMES. EACH YEAR, THE NMDP FOUNDATION IS PROUD TO INVEST IN RESEARCH THROUGH:THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM: THE AMY PROGRAM FUNDS EARLY CAREER INVESTIGATORS FOCUSED ON ADVANCES IN THE PREVENTION AND TREATMENT OF POST-CELL THERAPY COMPLICATIONS (E.G., GRAFT-VERSUS-HOST -DISEASE AND INFECTION).IN 2024, WE FUNDED THE WORK OF 14 AMY SCHOLARS. AMY SCHOLARS HAVE GONE ON TO BECOME LEADERS IN THE FIELD, PURSUING SCIENTIFIC ADVANCES THAT HELP NMDP PATIENTS LIVE LONGER, HEALTHIER LIVES. SINCE 1998, THE NMDP FOUNDATION HAS INVESTED NEARLY $12.5 MILLION TO HELP LAUNCH THE CAREERS OF 51 YOUNG PHYSICIAN-SCIENTISTS. AFTER RECEIVING THEIR NMDP AMY SCHOLAR AWARD, 51 YOUNG PHYSICIAN-SCIENTISTS HAVE GONE ON TO WIN MORE THAN $250 MILLION IN SUBSEQUENT GOVERNMENT GRANT FUNDING TO PURSUE THE DISCOVERIES TO HELP PATIENTS LIVE LONGER, HEALTHIER LIVES AFTER CELL THERAPY. TODAY, THE AMY STRELZER MANASEVIT RESEARCH PROGRAM FOR THE STUDY OF POST-CELL THERAPY COMPLICATIONS IS ONE OF THE LARGEST AND MOST COVETED FELLOWSHIPS IN THE FIELD OF TRANSPLANTATION.NMDP DONOR FOR ALL: THIS SERIES OF TRANSFORMATIONAL MULTI-CENTER CLINICAL TRIALS ARE TESTING A NEW TRANSPLANT PROTOCOL AIMED AT MAKING MISMATCHED DONOR TRANSPLANTS SAFER AND MORE EFFECTIVE, WITH THE GOAL OF EXPANDING ACCESS TO TRANSPLANT TO THOUSANDS OF PATIENTS WHO LACK A FULLY MATCHED DONOR.ANTHONY NOLAN TRUST: PROVIDE SUPPORT TO THE ANTHONY NOLAN RESEARCH INSTITUTE TO CONTINUE DEVELOPMENT AND MAINTENANCE OF AN HLA CLASS I AND II SEQUENCE DATABASE AND PROVISION OF HLA CLASS I AND II SEQUENCE INFORMATION.CIBMTR (THE CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) A PARTNERSHIP BETWEEN THE MEDICAL COLLEGE OF WISCONSIN AND NMDP IS THE LEADING HUB FOR TRANSPLANT AND CELL THERAPY RESEARCH. THE NMDP FOUNDATION HELPS TO FUND VARIOUS OTHER INNOVATIVE RESEARCH STUDIES LED AND MANAGED BY THE CIBMTR.

Program 3

Expenses: $44,586,836 Revenue: $0

RECRUITMENT:THE NMDP REGISTRY IS THE MOST DIVERSE LISTING OF POTENTIAL DONORS AND CORD BLOOD UNITS IN THE WORLD. EVERY SEARCH THROUGH NMDP PROVIDES PATIENTS WITH ACCESS TO MORE THAN 44 MILLION...

RECRUITMENT:THE NMDP REGISTRY IS THE MOST DIVERSE LISTING OF POTENTIAL DONORS AND CORD BLOOD UNITS IN THE WORLD. EVERY SEARCH THROUGH NMDP PROVIDES PATIENTS WITH ACCESS TO MORE THAN 44 MILLION POTENTIAL ADULT DONORS AND MORE THAN 820,000 CORD BLOOD UNITS WORLDWIDE. THE BEST MATCH FOR A PATIENT IS TYPICALLY SOMEONE WHO SHARES THEIR ETHNIC BACKGROUND. IMPROVING THE ETHNIC DIVERSITY OF THE NMDP REGISTRY IMPROVES ALL PATIENTS' ODDS OF FINDING THEIR BEST MATCH, REGARDLESS OF ETHNIC BACKGROUND.PEOPLE BETWEEN THE AGES OF 18 AND 30 ARE MOST URGENTLY NEEDED. RESEARCH HAS SHOWN THAT CELLS FROM YOUNGER DONORS LEAD TO BETTER LONG-TERM SURVIVAL FOR PATIENTS.IN FY24, MORE THAN 240,000 POTENTIAL DONORS JOINED THE NMDP REGISTRY AND MORE THAN 4,400 UMBILICAL CORD UNITS WERE ADDED TO THE REGISTRY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $56,094,143

Program Service Revenue $579,438,913

Investment Income $31,110,065

Other Revenue $24,661

TOTAL REVENUE $666,667,782

Expense Breakdown

Grants Paid $7,958,409

Salaries & Benefits $230,212,503

Fundraising Expenses $2,413,271

Program Expenses $516,586,076

Other Expenses $384,874,389

TOTAL EXPENSES $623,045,301

Year-over-Year Comparison

	2023	2022	Change
Revenue	$666,667,782	$577,983,771	+0.2%
Expenses	$623,045,301	$571,156,736	+0.1%
Net Income	$43,622,481	$6,827,035	+5.4%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✓ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

1784

Volunteers

18281

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$3,816,544

Total Directors

Key Employees

$4,990,281

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
BRIAN REITHEL	CHAIR	1.00	Officer Director	$0	$0	$0
JUDITH GASSON	CHAIR ELECT	1.00	Officer Director	$0	$0	$0
STEPHANIE LEE	VICE CHAIR	1.00	Officer Director	$0	$0	$0
ROBERT SOIFFER	SECRETARY	1.00	Officer Director	$0	$0	$0
LYNN ABRAHAMSEN	DIRECTOR	1.00	Director	$0	$0	$0
MELINDA CALTABIANO	DIRECTOR	1.00	Director	$0	$0	$0
URI HERZBERG	DIRECTOR	1.00	Director	$0	$0	$0
GARHENG KONG	DIRECTOR	1.00	Director	$0	$0	$0
MICHAEL LANG	DIRECTOR	1.00	Director	$0	$0	$0
ANNE MCGEORGE	DIRECTOR	1.00	Director	$0	$0	$0
RAVYN MILLER	DIRECTOR	1.00	Director	$0	$0	$0
VICKI RASMUSEN	DIRECTOR	1.00	Director	$0	$0	$0
ELIZABETH SHPALL	DIRECTOR	1.00	Director	$0	$0	$0
LAURIE STRONGIN	DIRECTOR	1.00	Director	$0	$0	$0
LORI MUFFLY	DIRECTOR	1.00	Director	$0	$0	$0
RAYNE ROUCE	DIRECTOR	1.00	Director	$0	$0	$0
AMY RONNEBERG	CHIEF EXECUTIVE OFFICER	48.00	Officer	$1,538,663	$455,038	$1,993,701
STEVEN DEVINE	CHIEF MEDICAL OFFICER	50.00	Officer	$900,352	$219,494	$1,119,846
KRISTA DUSIL	CHIEF FINANCIAL OFFICER (THRU 2/24)	49.00	Officer	$649,755	$53,242	$702,997
KATHERINE HEYERDAHL	CHIEF FINANCIAL OFFICER (BEGAN 4/24)	48.00	Officer	$0	$0	$0
MICHAEL MCCULLOUGH	CHIEF DIGITAL & INFORMATION OFFICER	47.00	Key Emp	$755,288	$56,963	$812,251
JULIE SMOLICH	SVP, PATIENT & PROVIDER SERVICES	49.00	Key Emp	$690,229	$202,137	$892,366
JAMIE MARGOLIS	SVP, DONOR & PRODUCT OPERATIONS	49.50	Key Emp	$618,634	$182,144	$800,778
JOY KING	CHIEF ADVANCEMENT OFFICER	30.00	Key Emp	$345,282	$168,631	$744,100
JEFFERY AULETTA	CHIEF SCIENTIFIC DIRECTOR	49.00	Key Emp	$719,360	$209,551	$928,911
ERICA JENSEN	SVP, INNOVATION, STRATEGY & MARKETING	49.00	Key Emp	$612,013	$199,862	$811,875
BRIAN LINDBERG	CHIEF ADMINISTRATIVE OFFICER	49.00	Highest	$863,511	$117,938	$981,449
PATRICIA JONES	SVP, HUMAN RESOURCES	49.00	Highest	$761,916	$11,133	$773,049
JOHN MILLER	VP, MEDICAL & QUALITY SERVICES	50.00	Highest	$730,844	$106,069	$836,913
HEATHER STEFANSKI	VP, CIBMTR & CLINICAL SERVICES	50.00	Highest	$535,863	$110,989	$646,852
MARY HENGEN	VP, CIBMTR & CLINICAL SERVICES	50.00	Highest	$484,493	$97,360	$581,853
GINA GRAVES	FORMER OFFICER	0.00		$239,958	$3,353	$243,311

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$666,667,782	$623,045,301	$402,742,599	$43,622,481
2023	$577,983,771	$571,156,736	$352,274,534	$6,827,035
2023	$577,983,771	$571,156,736	$352,274,534	$6,827,035
2022	$500,834,053	$508,871,683	$311,842,955	$-8,037,630
2021	$445,089,731	$465,546,094	$364,758,095	$-20,456,363
2020	$442,997,381	$445,447,669	$371,669,572	$-2,450,288
2019	$445,357,123	$429,047,103	$388,620,231	$16,310,020
2018	$418,299,785	$406,237,571	$365,800,299	$12,062,214